Mylan (Viatris)

Mylan (Viatris) Mylan (Viatris) is a multinational pharmaceutical company originally established in 1961 that became a major manufacturer of generic and specialty medicines, operating across North America, Europe, Asia, Africa, and Latin America. The company grew through acquisitions, strategic alliances, and vertical integration, interacting with corporations, regulators, investors, and health systems from Wall Street to the World Health Organization and engaging with markets such as India, China, Brazil, Germany, and the United Kingdom.

History

Mylan's origins trace to 1961 when founders Milan Puskar and Don Panoz launched a regional generics firm before expanding via mergers and acquisitions involving companies like Somerset Pharma, King Pharmaceuticals, and Matrix Laboratories, attracting attention from investors including Berkshire Hathaway and activist fund Elliott Management. The company listed on the New York Stock Exchange and engaged with regulators such as the United States Food and Drug Administration, the European Medicines Agency, and the Medicines and Healthcare products Regulatory Agency while navigating competition from Teva Pharmaceutical Industries, Sandoz, Novartis, Pfizer, and GlaxoSmithKline. Mylan pursued international expansion through joint ventures and purchases involving companies in India, China, Canada, and South Africa, and ultimately merged with Upjohn, a division of Pfizer, to form Viatris, a transaction that drew scrutiny from antitrust authorities including the Department of Justice, the European Commission, and national competition bureaus.

Corporate structure and ownership

The company's governance involved a board of directors, executive officers, and shareholders including institutional investors such as BlackRock, Vanguard Group, Elliott Management, and Berkshire Hathaway, and it maintained corporate headquarters and regional offices interacting with financial markets on the NYSE and NASDAQ as well as with rating agencies like Moody's and Standard & Poor's. Mylan's parentage under Viatris placed it within a multinational holding structure subject to corporate law in Delaware and regulatory filings with the Securities and Exchange Commission while coordinating operations across subsidiaries in jurisdictions including India, Ireland, Switzerland, Canada, and Australia. Strategic leadership changes connected figures with backgrounds at multinational firms and drew commentary from financial media outlets such as The Wall Street Journal, The New York Times, Financial Times, Bloomberg, and Reuters.

Products and global operations

Mylan produced a wide portfolio including branded generics, biosimilars, injectables, inhalers, and over-the-counter products with manufacturing sites and research centers in locations like Morgantown, Hyderabad, Bangalore, Philadelphia, and the Netherlands. Its product lines competed with offerings from companies such as Roche, Eli Lilly, Merck, Sanofi, AstraZeneca, Johnson & Johnson, Bayer, and AbbVie and were supplied to healthcare providers, hospitals, pharmacies, humanitarian agencies like Médecins Sans Frontières, and procurement bodies such as UNICEF and the Global Fund. Mylan's distribution networks interfaced with wholesalers and retailers including McKesson, Cardinal Health, Walgreens Boots Alliance, CVS Health, Walmart, and Amazon Pharmacy while addressing regulatory approvals from WHO prequalification, national health ministries, and reimbursement agencies such as NHS England and the Centers for Medicare & Medicaid Services.

Controversies and legal issues

The company was involved in high-profile disputes over pricing, patent litigation, regulatory inspections, and marketing practices that implicated courts and agencies such as the United States Department of Justice, the Federal Trade Commission, the European Commission, the Supreme Court of the United States, and district courts in multiple countries. Notable controversies included litigation over orphan drug designations, price increases scrutinized by Congress and state attorneys general, whistleblower suits under the False Claims Act, and settlements related to manufacturing quality and labeling that involved counterparts like Pfizer, Allergan, Hospira, and Actavis. The organization faced public attention from media investigations by ProPublica, The New York Times, The Washington Post, NPR, and broadcast outlets while advocacy groups such as Public Citizen, Consumers Union, and Health Action International criticized practices tied to access, affordability, and patent strategies.

Research, development, and collaborations

Mylan invested in research and development, clinical trials, and biosimilar pipelines, partnering with academic institutions, contract research organizations, and biotechnology firms including academic centers at Johns Hopkins University, University of Pennsylvania, Oxford University, and the Indian Institute of Science. Collaborations extended to alliances with companies and organizations such as Pfizer, Upjohn, Biocon, Medtronic, Roche, WHO, PATH, and Gavi in areas spanning vaccine delivery, antimicrobial access, and noncommunicable disease therapies, while engaging with funding bodies like the Gates Foundation and national research councils. Its R&D efforts were registered in trial registries, subject to peer review in journals such as The Lancet, New England Journal of Medicine, JAMA, and Nature Medicine, and conformed to guidelines by bodies including the International Council for Harmonisation and institutional review boards at major hospitals and universities.

Category:Pharmaceutical companies Category:Multinational companies Category:Generic drug manufacturers